PHAT — Phathom Pharmaceuticals, Inc. stock price, charts and financials
QT33Phathom Pharmaceuticals, Inc.Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
Latest market price
7.48
-0.27-3.48%
News
Down 3.5% — Phathom Pharmaceuticals (NASDAQ:PHAT) Reaches New 12-Month Low – Time to Sell? (defenseworld.net).
Medium confidence
TA
Loading chart...
Snapshot
| Index | - | P/E | - | EPS (ttm) | -1.28 | Insider Own | 32.16% | Shs Outstand | 80.90M | Perf Week | -10.53% |
| Market Cap | 605.14M | Forward P/E | 9.59 | EPS next Y | 0.78 | Insider Trans | 0.00% | Shs Float | 65.29M | Perf Month | -19.74% |
| Enterprise Value | 590.14M | PEG | - | EPS next Q | 0.07 | Inst Own | - | Short Float | 16.58% | Perf Quarter | -31.25% |
| Income | -99.00M | P/S | 2.52 | EPS this Y | 44.51% | Inst Trans | - | Short Ratio | 8.37 | Perf Half Y | -32.91% |
| Sales | 240.00M | P/B | - | EPS next Y | 209.80% | ROA | -30.29% | Short Interest | 10.82M | Perf YTD | -54.91% |
| Book/sh | -4.25 | P/C | 3.32 | EPS next 5Y | - | ROE | 25.70% | 52W High | 18.31 -59.15% | Perf Year | -32.00% |
| Cash/sh | 2.25 | P/FCF | - | EPS past 3/5Y | - | ROIC | -23.36% | 52W Low | 7.47 0.13% | Perf 3Y | -42.33% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | - | Gross Margin | 82.92% | Volatility | 5.65% 5.47% | Perf 5Y | -77.59% |
| Dividend TTM | - | EV/Sales | 2.46 | EPS Y/Y TTM | 75.80% | Oper. Margin | -16.96% | ATR (14) | 0.52 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 1.87 | Sales Y/Y TTM | 336.36% | Profit Margin | -41.34% | RSI (14) | 32.53 | Recom | 2.11 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.92 | EPS Q/Q | 73.42% | SMA20 | -14.31% | Beta | 0.45 | Target Price | 17.60 |
| Payout | 0.00% | Debt/Eq | 1.26 | Sales Q/Q | 85.00% | SMA50 | -21.40% | Rel Volume | 1.33 | Prev Close | 7.75 |
| Employees | 371 | LT Debt/Eq | -0.48 | Earnings | Oct 29 | SMA200 | -36.46% | Avg Volume | 1.35M | Price | 7.48 |
| IPO Date | Oct 25, 2019 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -19.60% 1.42% | Net Debt/EBITDA | 0.44 | Volume | 1,788,447 | Change | -3.48% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Sep-09-26 | Initiated | Leerink | Market Perform | $10 |
| Jul-31-26 | Reiterated | Craig-Hallum | Buy | $22 → $20 |
| Jul-31-26 | Reiterated | Guggenheim | Buy | $20 → $22 |
| Jul-30-26 | Reiterated | Needham | Buy | $26 → $22 |
| Mar-27-26 | Upgrade | Barclays | Equal Weight → Overweight | $16 → $18 |
| Feb-26-26 | Reiterated | Stifel Nicolaus | $24 → $28 | |
| Dec-11-25 | Initiated | Raymond James | Strong Buy | $28 |
| Dec-08-25 | Initiated | Barclays | Equal Weight | $16 |
| Oct-31-25 | Reiterated | Craig-Hallum | Buy | $17 → $22 |
| Oct-31-25 | Reiterated | HC Wainwright & Co. | Buy | $28 → $26 |
Latest News· Times ET
Sep-16-26
Sep-16-2611:41PM
04:00PM
Sep-09-26
Sep-01-26
Sep-01-2604:00AM
Aug-17-26
Aug-17-2605:57AM
Aug-04-26
Aug-04-2606:09AM
Aug-03-26
Aug-03-2606:07AM
Aug-01-26
Aug-01-2603:24PM
Jul-31-26
Jul-31-2606:07AM
Jul-30-26
Jul-30-2604:43PM
01:34PM
11:05AM
Phathom Pharmaceuticals Q2 Earnings Call Highlightsmarketbeat.com
09:23AM
Company
Phathom Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, dedicated to advancing and commercializing therapies for gastrointestinal ailments. A pivotal asset for the company is vonoprazan, a distinctive potassium-competitive acid blocker (P-CAB) designed to effectively inhibit gastric acid production, for which Phathom holds commercial rights across the United States, Europe, and Canada. This compound is currently undergoing advanced (Phase III) clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD), and also as a component of combination therapy with antibiotics to combat Helicobacter pylori (H. pylori) infection. Established in 2018, Phathom Pharmaceuticals maintains its corporate headquarters in Florham Park, New Jersey.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 240 | 175 | 55 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 41 | 23 | 8 | — | — | — | — | — | — | |
| Gross Profit | 198 | 153 | 47 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 209 | 280 | 291 | — | — | — | — | — | — | |
| Research and Development | 30 | 33 | 34 | — | — | — | — | — | — | |
| Other Operating Expense | 1 | -1 | 0 | — | — | — | — | — | — | |
| Operating Income | -40 | -160 | -277 | — | — | — | — | — | — | |
| Interest Expense | 63 | 68 | 72 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 4 | 7 | 15 | — | — | — | — | — | — | |
| Net Income Before Taxes | -99 | -221 | -334 | — | — | — | — | — | — | |
| Income Taxes | 0 | 0 | 0 | — | — | — | — | — | — | |
| Consolidated Net Income | -99 | -221 | -334 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | -99 | -221 | -334 | — | — | — | — | — | — | |
| Net Income | -99 | -221 | -334 | — | — | — | — | — | — | |
| EPS (Recurring) | -1.28 | -3.03 | -5.29 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -1.28 | -3.03 | -5.29 | — | — | — | — | — | — | |
| EPS (Diluted) | -1.28 | -3.03 | -5.29 | — | — | — | — | — | — | |
| EBITDA | -35 | -152 | -262 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 2.62 | 6.92 | 9.30 | — | — | — | — | — | — | |
| Gross Margin | 82.50 | 87.43 | 85.45 | — | — | — | — | — | — | |
| Operating Margin | -16.67 | -91.43 | -503.64 | — | — | — | — | — | — | |
| Net Margin | -41.25 | -126.29 | -607.27 | — | — | — | — | — | — | |
| Shares Outstanding | 84 | 73 | 63 | — | — | — | — | — | — | |
| Market Capitalization | 628 | 1,211 | 512 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Parikh Asit | Director | May 20 '26 | Option Exercise | 4.95 | 17,500 | 86,625 | 52,122 | May 21 |
| Parikh Asit | Director | Jan 13 '26 | Option Exercise | 10.30 | 8,750 | 90,125 | 131,000 | Jan 15 |
| Parikh Asit | Director | Dec 19 '25 | Option Exercise | 10.30 | 8,750 | 90,125 | 122,250 | Dec 23 |
| Basta Steven L | President and CEO | Nov 28 '25 | Option Exercise | 0.00 | 90,000 | 0 | 131,625 | Dec 02 |
| Breedlove Robert Charles | Principal Accounting Officer | Nov 03 '25 | Sale | 13.51 | 524 | 7,079 | 47,407 | Nov 05 |
| Basta Steven L | President and CEO | Sep 25 '25 | Option Exercise | 0.00 | 90,000 | 0 | 90,000 | Sep 26 |
| Breedlove Robert Charles | Principal Accounting Officer | Sep 05 '25 | Sale | 12.09 | 461 | 5,573 | 47,931 | Sep 09 |
| Breedlove Robert Charles | Principal Accounting Officer | Jul 16 '25 | Sale | 8.36 | 1,692 | 14,152 | 48,392 | Jul 18 |
| Topper James N | Director | May 21 '25 | Buy | 3.86 | 3,780 | 14,609 | 59,403 | May 23 |
| Topper James N | Director | May 14 '25 | Buy | 3.32 | 6,300 | 20,919 | 55,623 | May 15 |
| Topper James N | Director | May 13 '25 | Buy | 3.16 | 1,120 | 3,543 | 49,323 | May 15 |
| Topper James N | Director | May 12 '25 | Buy | 3.04 | 12,601 | 38,301 | 48,203 | May 13 |
| Topper James N | Director | May 09 '25 | Buy | 3.22 | 35,602 | 114,616 | 35,602 | May 13 |
| Parikh Asit | Director | May 07 '25 | Buy | 2.40 | 5,000 | 11,985 | 95,500 | May 08 |
| Parikh Asit | Director | May 06 '25 | Buy | 2.60 | 5,000 | 13,000 | 90,500 | May 08 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.